New cancer drug trial halted early – only 10 patients enrolled

NCT ID NCT06546553

First seen Nov 06, 2025 · Last updated May 01, 2026 · Updated 21 times

Summary

This early-stage study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the study was stopped early. Participants received treatment every 4 weeks and were followed for up to 4 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211, United States

  • Florida Cancer Specialists

    Orlando, Florida, 32827, United States

  • Florida Cancer Specialists & Research Institute, LLC

    Fort Myers, Florida, 33916, United States

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • START Mountain Region

    West Valley City, Utah, 84119, United States

  • START San Antonio

    San Antonio, Texas, 78229, United States

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida, 32827, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.